Paroxysmal Supraventricular Tachycardia Companies

Latest Paroxysmal Supraventricular Tachycardia (PSVT) Companies Updates:

Milestone Pharmaceuticals (NASDAQ: MIST): Milestone reported positive final results from their Phase 3 RAPID clinical trial testing etripamil for PSVT treatment. The drug met its primary endpoint with statistically significant results, potentially paving the way for FDA approval.

Iterum Therapeutics (NASDAQ: ITUM): Announced positive Phase 2b data for ITR-603, a novel non-stimulant oral medication for treating PSVT. The results showed favorable safety and efficacy, warranting further clinical development.

Medtronic (NYSE: MDT): Launched a clinical trial evaluating their Symplicity® System for treatment of PSVT patients with atrioventricular nodal re-entrant tachycardia (AVNRT), the most common type of PSVT.

Boston Scientific (NYSE: BSX): Received FDA approval for their Farapulse® catheter system, used for catheter ablation treatment of PSVT.

Biotronik (ETR: BIOT): Launched their EnRhythm® Supra system, a next-generation ablation catheter designed for precise PSVT treatment.

Abbott (NYSE: ABT): Received FDA approval for their Navicath Rhythm™ system, a mapping and navigation system for guiding catheter ablation procedures in PSVT treatment.

List of Paroxysmal Supraventricular Tachycardia (PSVT) companies in the market:

• GlaxoSmithKline PLC (U.K.)


• Novartis AG (Switzerland)


• Pfizer, Inc. (U.S.)


• AstraZeneca PLC (U.K.)


• Teva pharmaceutical industries (Israel)


• Sanofi SA (France)


• Medtronic, Inc. (U.S.)


• Glenmark Pharmaceuticals (U.S.)


• St. Jude Medical, Inc. (U.S.)


• BIOTRONIK SE & Co. KG (U.S.)


• GE Healthcare (U.S.)


• Boston Scientific Corporation (U.S.)